Compare IDEXX Laboratories, Inc. (IDXX) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Lemonade Inc — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Lemonade Inc trades at $46.5 (market cap $3.63B). The key difference: IDEXX Laboratories, Inc. is far larger — about 11.1× Lemonade Inc's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 1,544,794). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Lemonade Inc for 27 Days on average.
| IDXX | LMND | |
|---|---|---|
Market Cap | $40.43B | $3.63B |
Volume | 692,164 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $766.68 | $96.57 |
52-Week Low | $504.70 | $43.91 |
Typical Hold Time | 46 Days | 27 Days |
Enterprise Value | $41.32B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
LMND trades at $46.64, down 0.41% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains strong at 32% year-over-year in Q2 2026, with improving loss ratios and gross profit up 76%. The company is expanding geographically and expects its first EBITDA-positive quarter in late 2026, supported by AI-driven efficiency gains.
While LMND shows promising growth and path to profitability, the stock faces headwinds from persistent net losses, high valuation multiples, and mixed analyst sentiment. The consensus price target of $67.00 suggests 44% upside potential, but investors must weigh growth prospects against ongoing cash burn and competitive pressures in the insurtech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
